Introduction
Acute myeloid leukemia (AML) includes molecularly and biologically distinct subtypes of disease in which clonal populations of abnormal stem and progenitor cells give rise to a large population of proliferative myeloid blasts and other immature cell types (1) .
It has long been appreciated that recurrent cytogenetic and molecular abnormalities delineate distinct AML subtypes with differing biologic and clinical characteristics (2, 3) . It is also now well established that early stem and progenitor cell subsets (leukemia stem cells; LSCs) within the abnormal myeloid cell compartment contain the leukemia initiating activity of AML and likely mediate clinical relapse following therapy (4) (5) (6) . Although LSCs have been studied extensively in recent years, the relationship between the specific properties of LSCs and the clinical features of different disease subtypes remains poorly understood.
LSCs are hypothesized to mediate relapse on the basis of their relative quiescence (7, 8) and protective interactions with the bone marrow niche (9) . The evidence for the quiescence of AML stem cells is largely indirect, however. Most studies of human AML cells have been performed on samples treated in vitro or ex vivo with chemotherapy agents that kill bone marrow cells in S-phase, followed by the demonstration that surviving quiescent cells initiate disease in immunocompromised mice. Other studies have demonstrated that murine hematopoietic stem cells (HSCs) are generally quiescent in vivo; however, even in normal HSC populations 50% of the cells will enter S-phase within 6 days and >90% enter S-phase within 30 days (10) . A more important weakness of this hypothesis is the marked differences in chemotherapy responsiveness of different AML disease subtypes.
Chemotherapy alone cures 60 -79% of patients with core-binding factor AML (patients 
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with t(8:21), inv (16) , or t(16;16) cell karyotypes) (11, 12) , whereas patients with FLT3-ITD mutated AML have a 3-5 year overall survival (OS) rate of 20% -30% (3, 13) in spite of high rates of initial remission. This suggests that the resistance of LSCs to chemotherapy depends on the disease subtype; however, the molecular mechanisms that underlie these differences are largely unknown.
Recent years have witnessed an explosion in the genetic characterization of human malignancies in general and in AML in particular (14, 15) . The complete genomic sequencing of hundreds of AML samples has now been completed, and these analyses have demonstrated that the relatively small number of well-characterized mutations in AML (e.g., FLT3, NPM1, cKit, CEBPa) exist in a complex landscape of hundreds of other mutations (14, 15) . These studies have yielded promising new molecular targets for AML treatment, but how these mutations relate to the functional behaviors of these cells is not well understood. Furthermore, analysis of the largest cohort of sequenced AML samples revealed more than 100 unique combinations of known or suspected oncogenic mutations among 200 AML patients (14) . This complexity suggests that personalized treatment approaches cannot simply target all of the mutations present in a given patient's leukemia and that an understanding of how each mutation contributes to leukemia cell function (and which must be targeted in a given patient) will be required to fully realize the therapeutic promise of the knowledge obtained through genomic studies.
As a first step in addressing these issues, we report a mass cytometry-based approach for performing high-dimensional functional profiling of AML. The primary aim of this study was to directly measure the immunophenotypic, cell cycle, and intracellular signaling properties of AML cells that were processed and fixed immediately after bone 
Results

Immediate sample collection and barcoded staining resulted in consistent immunophenotypic and functional measurements by mass cytometry
Bone marrow aspirates were collected from 35 AML patients (18 newly diagnosed, 11 relapsed/refractory, one patient with relapsed myeloid sarcoma, and five patients with AML in complete remission (CR) at the time of sample collection), four patients with acute promyelocytic leukemia (APL), two patients with high-risk myelodysplastic syndromes (MDS; both transformed to AML within 60 days of biopsy), and five healthy donors (46 total biopsy samples). The clinical characteristics of the patients are listed in Supplementary Table 1. Two 39-antibody staining panels (with 23 surface markers and two intracellular markers common between them) were utilized for analysis (Supplementary Table 2 ). To ensure the consistency and accuracy of mass cytometric analysis, samples were collected immediately after bone marrow aspiration (<1 min), maintained at 37 °C prior to fixation, and frozen at -80 °C until the time of analysis. Samples were barcoded in groups of 20 to allow simultaneous antibody staining and mass cytometric analysis (17, 18). These protocols produced highly reproducible measurements of surface markers across replicates of the normal samples with an average coefficient of variation (CV) of 15.4%, with the majority of antibodies (39/45) 
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are consistent with prior studies (19) (20) (21) and confirmed that mass cytometry can be used with a high degree of reproducibility and accuracy for the analysis of AML clinical samples.
Distribution of cells across developmental stages is AML subtype specific
To perform immunophenotypic analysis of the mass cytometry data, both traditional gating and high dimensional SPADE clustering were performed using 19 of the surface markers common to both staining panels (Supplementary Table 2 ). The resulting SPADE analysis of the normal bone marrow was consistent across all of the healthy donors; an example from one healthy donor is shown in Figure 1 demonstrated that patients with core-binding factor mutations (CBF-AML; n=5; t(8;21), inv (16) , and t(16;16) karyotypes) and those with adverse-risk karyotypes (ARK-AML; n=6) had the highest prevalence of immature immunophenotypes, particularly hematopoietic stem cells (HSC; lin -CD34 + CD38 low CD45RA -CD90 + CD33 low ) and multipotent progenitor cells (MPPs; lin -CD34 + CD38 low CD45RA -CD90 -CD33 low ). The fractions of these two populations were increased more than 50-fold in CBF-AML and ARK-AML patients samples compared to healthy donors (p<0.002, in all comparisons). By contrast, patients with normal karyotype AML (NK-AML; with or without FLT3 mutation; n=17) and APL (n=4) exhibited much smaller increases of approximately three to ten-fold in the HSC and MPP populations.
The HSC and MPP populations of both CBF-AML and ARK-AML samples were significantly increased compared to these populations in NK-AML or APL (p values ranging from 0.0014
Research. were also detected in most non-myeloid immunophenotypic populations (including B, T, and NK cells), suggesting that the AML clone has wide-ranging effects in the bone marrow.
In addition to analysis of the total number of immunophenotypic aberrancies, specific aberrancies were also detected in patients with different AML subtypes. These 
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To confirm that high dimensional differences observed in the viSNE analysis could group samples based on AML subtype, the gated CD34 + CD38 low subset from each sample was analyzed by binning samples into 100 bins using a K-means clustering of the expression levels of the 19 markers used in the viSNE analysis. This independent analysis produced a hierarchical grouping of the samples based on the pairwise correlation of the distribution of cells across 100 multi-dimensional bins. This grouped all of the normal bone marrow samples into a single branch of the dendrogram (Supplementary Figure 3) . 
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AML subtypes are characterized by distinct patterns of cell cycle distribution
Given the important role of the proliferative rate in chemosensitivity, each immunophenotypic population was analyzed for cell cycle state (16) . Bone marrow aspirates from AML patients and healthy donors were exposed to iodo-deoxyuridine (IdU) immediately after collection (<1 min after aspiration) and incubated for 15 min at 37 °C followed by immediate fixation and storage. This method allowed for the closest possible Figure   7C ). The CD34 + CD38 low cell populations were least affected by HU treatment; there was no significant difference in S-phase fraction between samples from patients treated with HU and those who were not (2.72% vs. 2.86%; p=0. 21) Table 4) . High-dimensional mass or fluorescent cytometry approaches should therefore be able to rapidly identify at least some AML subtypes with high accuracy if internal staining controls are employed and analysis is restricted to the most predictive sub-gated populations (i.e., CD34 + CD38 low ).
Critically, the AML subtype-specific immunophenotypic changes observed were detected using four independent analyses to define the developmental subpopulations: manual gating by standard surface markers (gates defined solely on the basis of the normal samples), 19-dimensional SPADE clustering, viSNE analysis, and a K-means-based cell binning approach. The immunophenotypic populations within each AML sample with the greatest number of immunophenotypic aberrancies also had: (i) the greatest expansion relative to the normal population frequency (Figures 2 and 3 
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that high-dimensional analysis provides qualitatively different information from that obtained using standard diagnostic approaches and should enhance classification of malignant hematologic diseases.
High-dimensional cytometry enables assessment of AML LSC capabilities in vivo
To date, the functional properties of human leukemia stem cells have been almost exclusively studied in vitro or in the setting of murine transgenic (30) or xenograft models Conversely, despite relatively high rates of initial response to chemotherapy, patients with FLT3-ITD + AML are not commonly cured with consolidation chemotherapy alone (13) . The data presented in this report also fit well this observation: The LSCs in FLT3-ITD + patients would be expected to be resistant to cytarabine-based treatment by virtue of their low S-phase fraction (allowing disease relapse). Interestingly, the much more common myelo-monoblast cells in FLT3-ITD + AML patients exhibited the same Sphase fraction as samples from other AML subtypes and would thus be expected to be comparably sensitive to cytotoxic therapy (allowing for the initial responses generally observed in these patients; Figure 6D ).
Unique to this study is the ability to directly compare individual immunophenotypic populations in AML to the same populations in normal human bone marrow. This yielded While the sample size of this study allowed detection of highly significant differences between common AML subtypes, it remains small relative to the high degree of genomic complexity of AML and somewhat over-representative of patients with higher-risk subtypes. In the 24 samples from this cohort that were also tested for an expanded panel of somatic mutations, several additional mutations were detected. Of particular note was the common occurrence of DNMT3a mutations in FLT3-ITD + NK-AML patients (14, 15, 46), observed in four of the seven FLT3-ITD + NK-AML patients from this cohort (Supplementary Table 1 ). Due to the sample size, it was not possible to determine the additive effect of DNMT3a mutation in FLT3-ITD + NK-AML (though the three patients with wild-type DNMT3a all exhibited similar immunophenotypes and low S-phase fractions). Mass cytometric analysis of a much larger patient cohort should allow the functional consequences of these complex genetic interactions to be addressed.
In vivo functional profiling of AML to guide design of novel therapeutic strategies
Research. 
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This study provides an example of how characterization of the in vivo functional properties of LSCs can potentially inform the development of novel therapeutic strategies.
The finding that FLT3-ITD + AML LSCs have a significantly decreased S-phase fraction relative to other AML subtypes suggests that single-agent, high-dose cytarabine is unlikely to be a curative consolidation therapy for these patients. As such, these results also suggest two immunophenotypic targets, CD33 and CD123, could be exploited to treat these cells in a cell cycle-independent manner with antibody drug conjugates (ADCs). 
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immunotherapy approaches (e.g., chimeric antigen receptor T cells) could also be monitored. As understanding of the underlying genetic complexity of hematologic malignancies expands, real-time, functional measurement of therapy response will be increasingly important for understanding which of the many genetic lesions present in these diseases represent the most relevant targets for therapeutic intervention and how to best utilize the novel agents designed to target them.
Methods
Antibodies
Antibodies, manufacturers, and concentrations are listed in Supplementary Table 2 .
Antibody staining was performed in two overlapping panels, as indicated. Primary antibody transition metal-conjugates were either purchased or conjugated using 200-μg antibody lots combined with the MaxPAR antibody conjugation kit (Fluidigm Sciences, Toronto, Canada) according to the manufacturer's instructions. Following conjugation, antibodies were diluted to 100x working concentration in Candor PBS Antibody Stabilization solution (Candor Bioscience GmbH, Wangen, Germany) and stored at 4 °C.
Antibody coefficients of variation (CVs) were calculated by comparing the replicate analyses of aliquots of the healthy donor samples.
Human samples
Fresh bone marrow aspirates were collected immediately (<1 minute) after aspiration into 
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samples were obtained from Allcells (Emoryville, CA, USA) using the same protocol. The exception was healthy donor sample #1; this sample was incubated for ~1 hour with IdU at 37 °C. All healthy cell samples were collected into 15 μM IdU. Bone marrow cell samples were thawed just prior to analysis in a 4 °C water bath, and red cells were lysed using a hypotonic lysis buffer (SmartTube). Cells were then washed twice in cell staining medium (CSM; 1xPBS with 0.5% bovine serum albumin and 0.02% sodium azide) at room temperature.
Antibody staining
Prior to antibody staining, mass tag cellular barcoding was performed as previously Table 5) .
Immunophenotypic aberrancy analysis
Aberrant immunophenotype analysis was performed by first gating the normal populations into developmental immunophenotypic subsets on the basis of standard surface markers (as in Supplementary Figure 9 ). AML cells in each population were then compared to the normal samples across the 28 surface markers. Since the normal populations and AML samples were all stained and analyzed in the same tube simultaneously, the same gates were used to identify immunophenotypic populations from each of the AML samples. The median expression level of each maker in each gated population from each patient sample was then calculated. As the 14 replicate normal samples analyzed came from only five healthy donors, AML sample aberrancy was defined conservatively as an AML sample median expression level greater than or less than the : SPADE plots of normal bone marrow sample #6. SPADE clustering was performed on all samples (normal and AML) simultaneously to generate a single tree structure for all samples. All of the cell events from each sample were then mapped to the common tree structure. Each node of the SPADE tree is colored for the median expression of the indicated markers from low (blue) to high (red). The size of each node is correlated to the fraction of cells mapping to the node; however, a minimum size was enforced for most nodes to allow visualization of node color. Immunophenotypic grouping of nodes was performed manually on the basis of the median marker expression level of each node, and based on analysis of the relevant biaxial plots (e.g., CD38 vs. CD34). A) Method for defining aberrant marker expression. All immunophenotypic gates were defined on the basis of the normal samples and the same gates were applied to the each of the AML samples. Once each population was gated, the median expression of each of the 28 surface markers was extracted and compared to the median expression in the 14 samples from five healthy donors for each gated population. AML samples that were outside 2-fold the total variance of the normal samples were considered to be aberrant for that marker (CD45 is shown as an example). B) The total number of aberrant markers (of 28 measured markers) was summed for each population and each patient. Each box is colored for the number of the 28 markers that was aberrant for each patient (rows) in each gated immunophenotypic population (columns). The color scale ranges from green indicating no aberrant marker expression to the highest numbers of aberrancies colored red. The exact number of aberrant markers expressed (of the 28 tested) is printed in each box. The high rates of aberrancy observed in the pre-B cell population may be due in part to contamination of this gate with dimly CD19-positive malignant myeloid cells due to the limited number of markers defining this immunophenotypic subset (CD19 and CD10) and to the relatively dim staining of these antibodies in normal cells. Table 2 ). Two gates encompassing the vast majority of normal CD34 + CD38 low events are shown for reference. The AML subtype is indicated for each sample. Each cell event is colored for it's expression level of CD38 from blue (0 ion counts) to red (approximately 40 ion counts). Red cell events still fall within the CD34 + CD38 low gate and demonstrated dim CD38 expression. 
